Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 13/20 | 0.67 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.52 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.52 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.52 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.50 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.50 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.50 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.48 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | SHBG | P04278 | 1/20 | 0.47 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.47 |
| ▸ | AR | P10275 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL606838 | 0.86 | CYP19A1 (0.70) | CYP19A1GRIN1GRIN2AGRIN2BCYP17A1 | |
| SCHEMBL5676587 | 0.86 | CYP19A1 (0.70) | CYP19A1GRIN1GRIN2AGRIN2BCYP17A1 | |
| SCHEMBL3132563 | 0.85 | CYP19A1 (0.69) | CYP19A1GRIN1GRIN2AGRIN2BCYP17A1 | |
| SCHEMBL26964891 | 0.85 | CYP19A1 (0.69) | CYP19A1GRIN1GRIN2AGRIN2BCYP17A1 | |
| SCHEMBL28433832 | 0.84 | CYP19A1 (0.67) | CYP19A1SHBG | |
| SCHEMBL11740332 | 0.84 | CYP19A1 (0.67) | CYP19A1GRIN1GRIN2AGRIN2BCYP17A1 | |
| SCHEMBL11054544 | 0.83 | CYP19A1 (0.65) | CYP19A1GRIN1GRIN2AGRIN2BCYP17A1 | |
| SCHEMBL11054839 | 0.82 | CYP19A1 (0.64) | CYP19A1CYP17A1CYP1B1TBXAS1SRD5A1 | |
| SCHEMBL514562 | 0.82 | CYP19A1 (0.64) | CYP19A1GRIN1GRIN2AGRIN2BCYP17A1 | |
| SCHEMBL5479309 | 0.82 | CYP19A1 (0.74) | CYP19A1CYP17A1CYP1B1SRD5A2ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260148848-A1 | BIOMARKERS FOR DIAGNOSIS AND TREATMENT OF ENDOCRINE HYPERTENSION, AND METHODS OF IDENTIFICATION THEREOF | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2026-05-28 | — | — | US | claimed |
| EP-4740024-A1 | ENDOMETRIOSIS MARKERS AND METHODS OF DIAGNOSING ENDOMETRIOSIS | The University Court Of The University of Edinburgh (GB) | 2026-05-13 | — | — | EP | claimed |
| EP-4562182-A1 | BIOMARKERS FOR DIAGNOSIS AND TREATMENT OF ENDOCRINE HYPERTENSION, AND METHODS OF IDENTIFICATION THEREOF | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2025-06-04 | — | — | EP | claimed |
| WO-2025008638-A1 | ENDOMETRIOSIS MARKERS AND METHODS OF DIAGNOSING ENDOMETRIOSIS | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2025-01-09 | — | — | WO | claimed |
| US-20240047065-A1 | BIOMARKERS FOR DIAGNOSIS AND TREATMENT OF ENDOCRINE HYPERTENSION, AND METHODS OF IDENTIFICATION THEREOF | UNIVERSITY OF DUNDEE (GB) | 2024-02-08 | — | — | US | claimed |
| WO-2024023324-A1 | BIOMARKERS FOR DIAGNOSIS AND TREATMENT OF ENDOCRINE HYPERTENSION, AND METHODS OF IDENTIFICATION THEREOF | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2024-02-01 | — | — | WO | claimed |
| EP-4292102-A1 | BIOMARKERS FOR DIAGNOSIS AND TREATMENT OF ENDOCRINE HYPERTENSION, AND METHODS OF IDENTIFICATION THEREOF | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE - INSERM (FR) | 2023-12-20 | — | — | EP | claimed |
| WO-2022171680-A1 | BIOMARKERS FOR DIAGNOSIS AND TREATMENT OF ENDOCRINE HYPERTENSION, AND METHODS OF IDENTIFICATION THEREOF | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2022-08-18 | — | — | WO | claimed |
| EP-2396658-B1 | ASSAY FOR DETECTION OF ADRENAL TUMOUR | UNIV BIRMINGHAM (GB) | 2015-12-16 | — | — | EP | claimed |
| WO-2010092363-A1 | ASSAY FOR DETECTION OF ADRENAL TUMOUR | THE UNIVERSITY OF BIRMINGHAM (GB) | 2010-08-19 | — | — | WO | claimed |
| US-20260148848-A1 | BIOMARKERS FOR DIAGNOSIS AND TREATMENT OF ENDOCRINE HYPERTENSION, AND METHODS OF IDENTIFICATION THEREOF | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2026-05-28 | — | — | US | disclosed |
| EP-4740024-A1 | ENDOMETRIOSIS MARKERS AND METHODS OF DIAGNOSING ENDOMETRIOSIS | The University Court Of The University of Edinburgh (GB) | 2026-05-13 | — | — | EP | disclosed |
| EP-4562182-A1 | BIOMARKERS FOR DIAGNOSIS AND TREATMENT OF ENDOCRINE HYPERTENSION, AND METHODS OF IDENTIFICATION THEREOF | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2025-06-04 | — | — | EP | disclosed |
| WO-2025008638-A1 | ENDOMETRIOSIS MARKERS AND METHODS OF DIAGNOSING ENDOMETRIOSIS | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2025-01-09 | — | — | WO | disclosed |
| US-20240047065-A1 | BIOMARKERS FOR DIAGNOSIS AND TREATMENT OF ENDOCRINE HYPERTENSION, AND METHODS OF IDENTIFICATION THEREOF | UNIVERSITY OF DUNDEE (GB) | 2024-02-08 | — | — | US | disclosed |
| WO-2022171680-A1 | BIOMARKERS FOR DIAGNOSIS AND TREATMENT OF ENDOCRINE HYPERTENSION, AND METHODS OF IDENTIFICATION THEREOF | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2022-08-18 | — | — | WO | disclosed |
| CN-107840865-A | A kind of preparation method of methylprednisolone | 天津金耀集团有限公司 | 2018-03-27 | — | — | CN | disclosed |
| EP-2396658-B1 | ASSAY FOR DETECTION OF ADRENAL TUMOUR | UNIV BIRMINGHAM (GB) | 2015-12-16 | — | — | EP | disclosed |
| WO-2010092363-A1 | ASSAY FOR DETECTION OF ADRENAL TUMOUR | THE UNIVERSITY OF BIRMINGHAM (GB) | 2010-08-19 | — | — | WO | disclosed |
| WO-2010092363-A1 | ASSAY FOR DETECTION OF ADRENAL TUMOUR | THE UNIVERSITY OF BIRMINGHAM (GB) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260148848-A1 | BIOMARKERS FOR DIAGNOSIS AND TREATMENT OF ENDOCRINE HYPERTENSION, AND METHODS OF IDENTIFICATION THEREOF | SHBG, HSD11B2, HSD11B1 | CYP19A1 405/4885GRIN1 3694/4885GRIN2A 4153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.